Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNeuberger Berman Group LLC
Latest Disclosed Ownership93,496 shares
Latest Disclosed Value $ 30,935,094
Neuberger Berman Group LLC reports 18.84% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Neuberger Berman Group LLC filed a 13F-HR form disclosing ownership of 93,496 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $26,711,807 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 115,203 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -18.84% during the quarter. The current value of the position is $24,355,708 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 93,496 -21,707 -18.84 30,935 -32.47 0.0120
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 115,203 -15,341 -11.75 45,810 -23.04 0.0341
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 130,544 31,500 31.80 59,528 84.31 0.0435
2025-08-25 2025-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS Common 02043Q107 99,044 605 0.61 32,297 21.51 0.0249
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 99,044 605 32,297 0.0129
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 98,439 -11,269 -10.27 26,580 2.96 0.0223
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 109,708 3,511 3.31 25,815 -11.61 0.0205
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 106,197 10,789 11.31 29,207 25.98 0.0228
2024-11-14 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS Common 02043Q107 95,408 4,058 4.44 23,184 69.82 0.0190
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 95,408 4,058 23,184 0.0190
2024-11-14 2024-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS Common 02043Q107 91,350 19,686 27.47 13,652 -0.47 0.0113
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 91,350 19,686 13,652 0.0113
2024-11-14 2023-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS Common 02043Q107 71,664 -18,176 -20.23 13,717 -13.78 0.0120
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 71,664 -18,176 13,717 0.0120
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 89,840 -9 -0.01 15,911 -6.77 0.0145
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 89,849 397 0.44 17,066 -4.76 0.0153
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 89,452 28,682 47.20 17,919 24.08 0.0166
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 60,770 55,952 1,161.31 14,442 1,396.48 0.0142
2022-11-15 2022-09-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 4,818 123 2.62 965 40.88 0.0010
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 4,695 -1,590 -25.30 685 -33.24 0.0007
2022-05-23 2022-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS Common 02043Q107 6,285 2,584 69.82 1,026 85.53 0.0009
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 6,285 2,584 953 0.0004
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 3,701 3,701 553 0.0004
2019-05-13 2019-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 0 -2,871 -100.00 0 -100.00
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 2,871 0 0.00 209 -16.73 0.0003
2018-11-16 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS Common 02043Q107 2,871 -438 -13.24 251 -23.01 0.0003
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 2,871 -438 251
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 3,309 643 24.12 326 2.52 0.0004
2018-05-08 2018-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 2,666 0 0.00 318 -6.19 0.0004
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 2,666 0 0.00 339 8.31 0.0004
2017-11-15 2017-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 2,666 -207 -7.21 313 36.68 0.0004
2017-08-08 2017-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 2,873 2,873 229 0.0003
2017-02-06 2016-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 0 -3,031 -100.00 0 -100.00
2016-11-02 2016-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 3,031 3,031 0.00 205 0.0003
2015-07-31 2015-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 0 -4,500 -100.00 0 -100.00
2015-05-06 2015-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 4,500 4,500 0.00 470 0.0005
2015-02-05 2014-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 0 -4,500 -100.00 0 -100.00
2014-11-04 2014-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 4,500 4,500 -80.35 351 -76.06 0.0004
2014-02-11 2013-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 0 -22,900 -100.00 0 -100.00
2013-10-29 2013-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 22,900 22,900 1,466 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.